Stay updated on Safety of CVL-231 in Schizophrenia: Clinical Trial

Sign up to get notified when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of CVL-231 in Schizophrenia: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:09:48.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant content removal, particularly regarding the details of a clinical trial for emraclidine in schizophrenia, including the study's purpose, inclusion and exclusion criteria, and the previous version's revision number. The only notable addition is a new revision number.
    Difference
    23%
    Check dated 2025-04-16T17:40:12.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The page has been updated to include AbbVie and ABBVIE INC., while removing references to Cerevel Therapeutics, LLC and Lawrence Park. Additionally, the revision number has been updated to v2.14.4.
    Difference
    1%
    Check dated 2025-04-09T13:05:51.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.14.3) and a more recent last update date of March 25, 2025, replacing the previous version (v2.14.2) and date of February 12, 2025.
    Difference
    0.3%
    Check dated 2025-04-01T23:58:14.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T22:53:06.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The study has reduced its locations from 97 to 85, with significant changes in the geographical areas covered, including the removal of several locations in the United States and Bulgaria. Additionally, the study contact information has been removed.
    Difference
    13%
    Check dated 2025-02-17T19:01:29.000Z thumbnail image

Stay in the know with updates to Safety of CVL-231 in Schizophrenia: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.